An Open-Label, Multiple-Dose, Non-Randomized Study to Assess the Drug-Drug Interactions of Proellex (CDB-4124) With Cytochrome P450 Isoenzymes CYP1A2, 2C9, 2C19, 2D6, and 3A4 in Healthy Female Subjects.

Trial Profile

An Open-Label, Multiple-Dose, Non-Randomized Study to Assess the Drug-Drug Interactions of Proellex (CDB-4124) With Cytochrome P450 Isoenzymes CYP1A2, 2C9, 2C19, 2D6, and 3A4 in Healthy Female Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2014

At a glance

  • Drugs Telapristone (Primary)
  • Indications Breast cancer; Endometriosis; Uterine leiomyoma
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 27 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top